Skip to content

Clinical trials

Neuroectodermal Tumors, Primitive, Peripheral trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Neuroectodermal Tumors, Primitive, Peripheral Clear all

134 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20004
200111
20026
20034
20047
200510
20065
20078
200810
20091
20104
20113
20123
20133
20144
20151
20163
20178
20187
20204
20212
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed97
Terminated13
Active, not recruiting10
Unknown status7
Withdrawn5
Recruiting2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)37
Children's Oncology Group21
Memorial Sloan Kettering Cancer Center9
City of Hope Medical Center7
National Institutes of Health Clinical Center (CC)5
Children's Cancer and Leukaemia Group3
Dana-Farber Cancer Institute3
Institut Curie3
Milton S. Hershey Medical Center3
St. Jude Children's Research Hospital3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Neuroectodermal Tumors, Primitive, Peripheral134
Sarcoma95
Osteosarcoma70
Neuroblastoma59
Medulloblastoma39
Wilms Tumor39
Rhabdomyosarcoma36
Central Nervous System Neoplasms34
Sarcoma, Ewing25
Astrocytoma24

Trials

Showing 26 to 50 of 134. Each trial links to its page on Pharma Observatory.

34 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.